Innovent Biologics unveiled preliminary data from its first-in-human trial of the trispecific antibody IBI3003, demonstrating favorable safety and encouraging efficacy signals, especially at doses above 120 μg/kg. The drug targets multiple tumor antigens to overcome resistance in relapsed/refractory multiple myeloma, showing promising activity in high-risk patients with extramedullary disease or prior treatments. Longer-term results are awaited as the company advances in ongoing clinical trials targeting difficult-to-treat myeloma cases.